-
Mashup Score: 1Bridging Therapy Responses May Outcomes With Axi-Cel Administration in Real-World Setting - 4 month(s) ago
High disease burden may be associated with more bridging therapy use and contribute to worse outcomes, according to investigators.
Source: www.oncnursingnews.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3What New Cancer Drugs Were Approved in 2023? - 4 month(s) ago
In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
Source: www.oncnursingnews.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 3What New Cancer Drugs Were Approved in 2023? - 4 month(s) ago
In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
Source: www.oncnursingnews.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 1Bridging Therapy Responses May Outcomes With Axi-Cel Administration in Real-World Setting - 4 month(s) ago
High disease burden may be associated with more bridging therapy use and contribute to worse outcomes, according to investigators.
Source: www.oncnursingnews.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Bridging Therapy Responses May Outcomes With Axi-Cel Administration in Real-World Setting - 4 month(s) ago
High disease burden may be associated with more bridging therapy use and contribute to worse outcomes, according to investigators.
Source: www.oncnursingnews.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Enfortumab Vedotin Plus Pembrolizumab Snags Full Approval for Patients With Locally Advanced or Metastatic Urothelial Cancer - 4 month(s) ago
The FDA has granted approval to enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer.
Source: www.oncnursingnews.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Opinion: CAR T-Cell Therapy Remains a Promising Therapeutic Option Despite FDA Inquiry into Secondary Malignancies - 5 month(s) ago
Oncology nurses should be ready to offer informative guidance to patients and their families concerning the ongoing FDA inquiry and its potential impact.
Source: www.oncnursingnews.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Opinion: CAR T-Cell Therapy Remains a Promising Therapeutic Option Despite FDA Inquiry into Secondary Malignancies - 5 month(s) ago
Oncology nurses should be ready to offer informative guidance to patients and their families concerning the ongoing FDA inquiry and its potential impact.
Source: www.oncnursingnews.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Opinion: CAR T-Cell Therapy Remains a Promising Therapeutic Option Despite FDA Inquiry into Secondary Malignancies - 5 month(s) ago
Oncology nurses should be ready to offer informative guidance to patients and their families concerning the ongoing FDA inquiry and its potential impact.
Source: www.oncnursingnews.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Oncology Drug Crash Course: Elacestrant (Orserdu) - 7 month(s) ago
Kristine Gibbons, RN, OCN, who is a Nurse Trainer at Florida Cancer Specialists & Research Institute, provides an in-depth look at elacestrant in a downloadable fact sheet.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Bridging Therapy Responses May Outcomes With Axi-Cel Administration in Real-World Setting #oncology #nursing https://t.co/h8zQFaLOfS